Vertex Pharmaceuticals Q3 FY25: where the revenue came from and where it went
The whole income statement of Vertex Pharmaceuticals for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2025
- Reported
- Nov 4, 2025
Revenue$3.08B
+11% year over year
Gross profit$2.66B
87% margin
Operating profit$1.19B
39% margin
Net profit$1.08B
35% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 3.08 | 100% | +11% |
| Trikafta/Kaftrio | 2.65 | 86% | +3% |
| Alyftrek | 0.25 | 8% | |
| Manufactured product other | 0.18 | 6% | −6% |
| Cost of revenue | −0.42 | 13% | |
| Gross profit | 2.66 | 87% margin | +1pp |
| SG&A | −0.45 | 14% | +1pp |
| Other | −1.03 | 34% | +0pp |
| Operating profit | 1.19 | 39% margin | −2pp |
| Other income, net | 0.11 | ||
| Tax | −0.22 | ||
| Net profit | 1.08 | 35% margin | −3pp |
175 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest